Rationale: 3ʹ,5ʹ-Cyclic guanosine monophosphate (cGMP) is an important second messenger that regulates cardiac contractility and protects the heart from hypertrophy. However, because of the lack of real-time imaging techniques, specific subcellular mechanisms and spatiotemporal dynamics of cGMP in adult cardiomyocytes are not well understood.
3 ʹ,5ʹ-Cyclic guanosine monophosphate (cGMP) is one of the ubiquitous second messengers, which is critically involved in the regulation of cardiac contractility and pathological hypertrophy. 1, 2 In cardiomyocytes, 2 classes of guanylyl cyclases (GCs) are responsible for cGMP synthesis. The first class, particulate GCs (pGCs) represented by GC-A and GC-B, are plasma membrane receptors for atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), respectively. 3, 4 Second, the so-called soluble or NO-sensitive GCs (NO-GCs) are also functionally present in cardiomyocytes. [5] [6] [7] cGMP levels are negatively regulated by cGMP-hydrolyzing enzymes phosphodiesterases (PDEs) with at least 4 families (PDE1, 2, 3, and 5) expressed in cardiac myocytes, whereby the first 3 PDEs can degrade both cGMP and cAMP. [8] [9] [10] [11] cGMP is generally considered as a cardioprotective second messenger, 12 because pharmacological elevation of cGMP levels either by inhibition of cGMP-hydrolyzing PDE5 and PDE1 or by activation of NO-GC and pGC prevents pathological cardiomyocyte growth in vitro 13 and cardiac remodeling in vivo. 2, [14] [15] [16] fashion, 1, 8 so that robust techniques to monitor this second messenger with high sensitivity and temporal and spatial resolution are desirable. During the past decade, several optical and nonoptical methods to measure cGMP in single intact cells have been developed. Electrophysiological recordings using ectopically expressed cyclic nucleotide gated channels as sensors for subsarcolemmal cGMP have uncovered differential contributions of various PDE families in compartmentation of cGMP in adult rat ventricular myocytes. In particular, GC-A-derived cGMP is exclusively controlled by PDE2, whereas PDE5 exclusively controls cGMP pools produced by NO-GC under physiological conditions. 18 However, this technique has certain limitations such as restriction of the sensor to the subsarcolemmal compartment and relatively low cGMP/cAMP selectivity. 19 In parallel, several fluorescent cGMP biosensors have been developed that allow visualization of intracellular cGMP with high temporal and spatial resolution. 20 Most of these sensors are based on a partially truncated cGMP-dependent protein kinase molecule that changes its conformation on cGMP binding, thereby leading to a change in Förster resonance energy transfer (FRET) between cyan and yellow fluorescent proteins fused to the kinase backbone, [21] [22] [23] or to an increase in fluorescence of circularly permuted green fluorescent protein attached to its C-terminus. 24 These sensors represent a major advance in cGMP imaging, but have either relatively low sensitivity (≈1 μmol/L affinity for cGMP, which is ≈5-10 times less than the affinity of cGMP-dependent protein kinase) or, again, very low cGMP/cAMP selectivity. These sensors were successfully used to uncover compartmentalized cGMP signaling in neonatal rat cardiomyocytes, 25, 26 but failed to robustly report cGMP in adult myocytes that produce much less cGMP.
Recently, a low-affinity biosensor 27 based on a single regulatory cGMP-binding domain from PDE5 has been modified by exchanging cyan and yellow with green (T-Sapphire) and red (Dimer2) fluorescent proteins. Unexpectedly, this modification led to ≈40-fold increase in the affinity for cGMP (40 nmol/L versus 1.5 μmol/L) together with the retained low affinity for cAMP (>1 mmol/L), 28 making this biosensor (called red cGES-DE5) promising for cGMP measurements in adult cardiomyocytes. Here we transgenically expressed this biosensor in adult mouse ventricular myocytes and showed that in these cells basal cGMP levels are as low as ≈10 nmol/L, can be markedly stimulated by pGC ligands, especially by the CNP, and that they are dynamically regulated by the activities of NO-GC and several PDE families. We think that this new transgenic cGMP-FRET sensor mouse should become a widespread tool for the visualization of cGMP in adult cardiomyocytes under physiological and pathophysiological conditions.
Methods
The expanded Methods section is available in the Online Data Supplement.
Transgenic Mice
DNA encoding the red cGES-DE5 sensor was excised from the original pcDNA3.1-based vector 28 and subcloned via KpnI and XhoI restriction sites into the previously described vector containing the α-myosin heavy chain promoter and polyadenylation signal. 29 The resulting vector was linearized with SpeI, purified, and used for pronuclear injections to generate transgenic mice on the FVB/NRj background (obtained from Janvier Laboratories, Saint Berthevin, France) as described. 30 All the procedures involving mice were in accordance with institutional and governmental guidelines.
FRET Measurements
Single adult mouse ventricular cardiomyocytes were freshly isolated and subjected to FRET measurements as previously described. 31 Red cGES-DE5 was excited with 405 nm light from Polychrome V (Till Photonics). Emission light was split into donor and acceptor channels using the DV2 QuadView (Photometrics) equipped with the 565dcxr dichroic mirror and BP515/30 and BP590/40 emission filters. Changes in FRET were monitored at room temperature on bath application of various ligands using VisiView imaging software (Till Photonics). The raw data were corrected offline for the bleedthrough of the donor into the acceptor channel and for photobleaching as described. 31
Transverse Aortic Constriction
Mice 9 to 13 weeks old were randomized to sham or transverse aortic constriction (TAC) group. Mice were anesthetized using 1.5% to 2% isoflurane in pure O 2 . A suprasternal incision was made and the aortic arch visualized using a binocular macroscope (Olympus). TAC 32 occurred by spacer-defined (26-gauge) constriction using a 6-0 polyviolene suture between the first and second trunk of the aortic arch. For sham, the aorta was not constricted. Three days after surgery, Doppler velocity was measured by a 20 MHz probe to quantify the pressure gradient across the TAC or after sham procedure by transthoracic echocardiography (VisualSonics; Vevo 2100, Toronto, Canada). Mice received analgesic therapy with metamizole 3 days before and for 1 week after surgery. Mice were analyzed by echocardiography and euthanized 8 to 9 weeks after surgery for ventricular cardiomyocyte isolation and single-cell microscopy.
Statistics
Morphometric, echocardiographic, working heart, radioimmunoassay (RIA), and FRET data were analyzed using Origin Pro 8.6 software (OriginLab Corporation, Northhampton, MA) and presented as mean±SE from the indicated number of independent experiments (animals) per condition. Numbers of mice and single cells are indicated in figure legends and above the bars in the graphs. Raw data were analyzed for normal distribution using the Kolmogorov-Smirnov test. When normally distributed, data were compared using mixed ANOVA followed by χ 2 test, or 1-way ANOVA for simple 2-group comparison. Otherwise, nonparametric tests (Kruskall-Wallis followed by Dunns test or Mann-Whitney) were applied. Differences were considered significant at P<0.05.
Results

Generation of Red cGES-DE5 Transgenic Mice
To be able to measure cGMP levels in freshly isolated adult cardiomyocytes, we generated transgenic mice by pronuclear injection of a construct that expresses this biosensor under the control of the α-myosin heavy chain promoter ( Figure 1A ). Two PCRpositive founders were obtained, 1 of which bred normally and gave rise to a phenotypically normal line of offspring. Cardiac morphology and heart function in these mice were not affected by sensor expression, as demonstrated by histological, morphometric, and echocardiographic analysis performed at the age of 6 months ( Figure 1B -1D; Online Table I ). The heart to body weight ratios were also not changed at 3 months of age (4.9±0.1 for both wild-type and transgenic mice; n=12-14), as were the heart weight to tibia length ratios (68.6±2.4 and 68.1±1.2 for wild-type and transgenic mice, respectively; n=12-14). There was also no difference in cell size, as measured in WGA-stained transverse heart sections ( Figure 1E ). Next, we isolated adult cardiomyocytes from these mice and observed strong green and red cytosolic fluorescence in T-Sapphire and Dimer2 channels in all transgenic cells ( Figure 1F ).
FRET Measurements of cGMP Synthesis and Degradation
To analyze cGMP levels in real time, we used freshly isolated transgenic ventricular myocytes and stimulated them with ligands that activate NO-GC, GC-A, and GC-B. Interestingly, FRET signals induced by NO donors, such as sodium nitroprusside (Online Figure I) and
S-nitroso-N-acetyl-d,l-penicillamine (SNAP), were not present in every cell (Figure 2A and 2E). Even NO donors with faster kinetics of release such as diethylamine NONOate and PROLI NONOate did not evoke any signal (Online Figure  I ). However, some basal NO-GC activity was clearly present ( Figure 6 ), and SNAP application after combined prestimulation with β-adrenergic receptor agonist and PDE5 inhibitor tadalafil showed small but clear FRET responses (see below). In contrast, pGC ligands at saturating concentrations increased cGMP, although with variable amplitudes but to much higher levels, especially the GC-B agonist CNP that evoked significantly stronger cGMP responses than the GC-A ligand ANP ( Figure 2B -2E; Online Figure II ). The absence of sensor response to NO donors and negligible response to ANP were unlikely the result of improper sensor localization, because in neonatal rat cardiomyocytes, which express ≈3-fold higher levels of NO-GC, red cGES-DE5 showed clear responses to SNAP and ANP (Online Figure III) , which exactly reflected the behavior of these cells reported previously using other FRET biosensors. 6, 25 Quantification of basal and stimulated cGMP levels in adult mouse myocytes using RIA performed in the presence of 3-isobutyl-1-methylxanthine (IBMX) revealed comparable magnitudes of responses as measured by FRET in the presence of IBMX ( Figure 2F ), suggesting that the sensor properly reflects overall changes of cGMP in the cytosolic compartment of adult mouse cardiomyocytes.
To study whether the cGMP-FRET data acquired in single isolated cells correlate with cGMP levels and cGMP-dependent protein kinase activity in intact beating hearts, we stimulated working hearts the same way and performed cGMP-RIA and immunoblot analysis of cardiac cGMP-dependent protein kinase substrate phospholamban 33 phosphorylation in left ventricular tissue. These experiments showed a robust effect of CNP and a slight stimulatory effect of SNAP on cGMP levels but not on PLN phosphorylation (Figure 3 ). Interestingly, ANP did not affect cGMP levels, which was in contrast to previously observed ≈2.5-fold increase in C57BL/6;129 mice under the same conditions. 34 This might argue for the differences of GC-A expression between various genetic backgrounds.
Next, we tested the contribution of various PDEs involved in cGMP degradation at basal state by the use of selective PDE1, 2, 3, and 5 inhibitors. The PDE1 inhibitor 8-methoxymethyl-3-isobutyl-1-methylxanthine applied alone had no effect on basal cGMP levels ( Figure 4A ). Unexpectedly, cGMP levels were increased by the selective PDE3 inhibitor cilostamide, whereas the selective PDE2 and PDE5 inhibitors BAY-60-7550 and tadalafil, respectively, showed only negligible effects ( Figure 4B-4D ). The effect of cilostamide at 10 μmol/L was as strong as that of the unselective PDE inhibitor IBMX applied alone (100 μmol/L; Figure 4E ). Clear effects of cilostamide and IBMX alone also indicated that there is a source of basal cGMP production.
An important advantage of transgenic sensor mice is the possibility of combining them with various genetic and experimental disease models. To this end, we studied whether the relative contributions of different PDEs might be changed in cardiac disease and performed TAC to induce a mild compensated pressure overload cardiac hypertrophy (Online Table  II ). We isolated cardiomyocytes from TAC and sham-operated mice to perform similar experiments as shown in Figure 4E . Interestingly, although there was no difference in maximal CNP plus IBMX response (11.6±1.4% and 10.3±1.3% in TAC versus sham; n=24 cells from 4 to 6 mice), we could observe a significant increase of PDE5 inhibitor effect ( Figure 4F ). In contrast to previously described upregulation of PDE1 and downregulation of PDE3 activities under more intense hypertrophy conditions, 15, 35 the responses to PDE1 and PDE3 inhibitors were unchanged in our mild TAC model ( Figure 4F ).
Next, we studied the role of individual PDE families in the hydrolysis of cGMP under stimulated conditions, such as occurring in intact heart and in disease. We first pretreated the cells with a low dose of isoproterenol (ISO) to mimic physiological catecholamine-stimulated cAMP concentrations or with angiotensin II in combination with bone natriuretic peptide to mimic pathological conditions and then inhibited PDEs ( Figure 5A and 5B ). Under these conditions, which are more close to the situation in intact heart, cilostamide effects were still present, suggesting that PDE3 continued to play its important role in cGMP hydrolysis. In the presence of competitive substrate cAMP, cilostamide effects were reduced by ≈50% but still remained significantly stronger than those of other PDE inhibitors ( Figure 5A ). Likewise, after prestimulation with CNP ( Figure 5C ), ANP, or SNAP, strong cilostamide effects were unchanged (Online Figure IV) .
Basal cGMP Levels Are Low in Adult Cardiomyocytes
To estimate absolute basal cGMP concentrations in the cytosol of adult mouse myocytes and to identify the source of basal cGMP production, we measured FRET responses to the NO-GC inhibitor 1H- [1, 2, 4] oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ), which should decrease cGMP levels to minimal levels measurable by the sensor. Within a few minutes, ODQ 50 μmol/L led to an increase of FRET ratio by 4.0±0.7%, which is indicative of a decrease of basal cGMP. The response to IBMX after ODQ application was virtually abolished ( Figure 6A and 6B) , whereas the pGC inhibitor A71915 showed no effect on FRET ratio ( Figure 6B ), suggesting that the NO-GC activity is primarily responsible for basal cGMP production. When compared with maximal FRET responses evoked by CNP plus IBMX (14.4±1.9%; Figure 2E ) and the concentration-response curve of red cGES-DE5 sensor protein to cGMP measured in vitro, 28 basal cGMP levels in adult mouse cardiomyocytes can amount to ≈10 nmol/L.
PDE3 Is Involved in cGMP/cAMP Crosstalk
cGMP has been shown to affect cardiomyocyte cAMP levels in 2 ways. It can either decrease cAMP via PDE2 activation or increase it via PDE3 inhibition, 9 which in neonatal cardiomyocytes depends on the studied cAMP microdomain. 25 We wondered which of these mechanisms plays the predominant role after β-adrenergic stimulation in the cytosol of adult mouse cardiomyocytes. To answer this question, we used ventricular cardiomyocytes isolated from mice transgenically expressing the cAMP sensor Epac1-camps. 36 These cells react to the β-adrenergic receptor agonist ISO with an increase of cAMP, which is visualized by a decrease of FRET. Subsequent application of CNP or, to a smaller extent, ANP led to a further significant increase in cAMP levels ( Figure 7A and 7B) . In contrast, the application of 100 nmol/L CNP alone did not lead to any significant response (0.38±0.38% of ISO; n=13 cells from 2 hearts). The PDE3 inhibitor cilostamide increased cAMP after ISO ( Figure 7E and 7F) , whereas the inhibition of PDE2 with BAY-60-7750 could not further raise intracellular cAMP after CNP application (115.9±4.4%; n=9 cells from 3 mice), suggesting that after β-adrenergic stimulation, the increase in intracellular cGMP leads to an increase of cytosolic cAMP levels due to PDE3 inhibition. The stimulatory effects of ANP and CNP after ISO were abolished in cells preincubated with cilostamide, confirming the central role of PDE3 in this type of cGMP/cAMP crosstalk (Figure 7C, 7D, and  7F) . This finding suggests that in isolated adult mouse cardiomyocytes, PDE3 is involved in controlling the natriuretic peptide-stimulated cGMP pools responsible for cGMP/cAMP crosstalk. Interestingly, pretreatment of cells with the PDE5 inhibitor tadalafil did not significantly affect ANP and CNP responses but strongly augmented the response to SNAP ( Figure 7F ). Therefore, we monitored cGMP levels under the same stimulatory conditions. Combined application of TAD and SNAP after ISO now led to measurable FRET responses (3.7±0.4%; n=12 cells from 3 mice), suggesting that the transgenic sensor is capable of detecting the cGMP pool, which is produced by NO-GC after β-adrenergic stimulation and controlled by PDE5.
Discussion
Initially, we generated transgenic mice with an older low-affinity (≈0.9 μmol/L) cGMP biosensor cGES-DE2 but could not detect any change in FRET on NO-GC and pGC stimulation in adult cardiac myocytes. Therefore, we hypothesized that only a highly sensitive FRET sensor can be used for cGMP imaging in these cells, whereas other biosensors, including cGi500 (affinity ≈0.5 μmol/L), for which an ubiquitous transgenic mouse has recently been published, 37 would not pick up low cGMP levels typical for adult cardiomyocytes. Here we generated transgenic mice expressing a highly sensitive cGMP biosensor red cGES-DE5 and used them for FRET measurements. To our knowledge, this is the first report on real-time FRET-based cGMP imaging in adult mouse cardiomyocytes.
Constitutive transgenic expression of the sensor in mouse hearts did not lead to any phenotypic abnormalities as shown by morphometric analysis and echocardiography (Figure 1 ; Online Table I ). The sensor was uniformly expressed in the cytosol of all cardiomyocytes at a high enough level to allow reliable FRET measurements. Interestingly, most of the cells did not respond to NO-GC stimulation by NO donors, suggesting that NO-GC is neither highly expressed in these cells nor accessible to bioactive NO generated by these substances in cardiac myocytes. Indeed, previous reports in adult mouse cardiomyocytes suggested a relatively low NO-GC expression 38 ; these cells expressed ≈3-fold less NO-GC compared with neonatal cardiomyocytes (Online Figure IIIB) ; and the effects of exogenous NO donors in ventricular (contrary to atrial) myocytes have been inconsistent. In addition, high concentrations of myoglobin might partially prevent NO-dependent effect due to its scavenging. 39 Another possibility is that the concentration of the cytosolic sensor in NO-GC-associated microdomain is not high enough to monitor cGMP on direct stimulation. However, we were able to observe a clear effect of SNAP in neonatal rat cardiomyocytes (Online Figure III) and absence of any effect in RIA measurements ( Figure 2F ), which would argue against improper Figure 5 . Analysis of phosphodiesterase (PDE) inhibitor effects on 3ʹ,5ʹ-cyclic guanosine monophosphate (cGMP) levels at prestimulated state. Cardiomyocytes were first prestimulated for 5 min with 0.1 nmol/L isoproterenol (ISO; A), with a combination of 100 nmol/L angiotensin II (AngII) plus 100 nmol/L bone natriuretic peptide (BNP) to mimic neurohormonal stimulation in disease (B), or with 100 nmol/L C-type natriuretic peptide (CNP; C) to increase cGMP levels, and PDE1, 2, 3, and 5 inhibitors were applied as described in Figure 4A -4E to measure changes in Förster resonance energy transfer (FRET) ratio evoked by each PDE inhibitor. The numbers of mice and cells per condition are shown above the bars (as n cells/N mice). Significant differences (P<0.05) are indicated with asterisks. localization of the sensor. In contrast, previously published data documented small but significant increases of cardiomyocyte cGMP after NO donor stimulation in C57BL/6 myocardium, 40 which was also the case in our working heart experiments. We also tested the possibility that the isolation procedure might lead to oxidation and loss of NO sensitivity of NO-GC. Even when all isolation steps and measurements were performed in the presence of the reactive oxygen species scavenger melatonin (100 μmol/L), 41 no response to NO donors could be attained. In addition, the direct NO-GC activator BAY-58-2667 (cinaciguat) capable of activating even oxidized NO-GC 42 did not show any response (Online Figure  I ), suggesting that cardiomyocyte isolation per se is unlikely to inactivate NO-GC. However, under combined ISO and TAD treatment, NO donor effects could be unmasked, which supports the previously established stringent compartmentation of NO-GC/cGMP pools by PDE5 after β-adrenergic stimulation (Online Figure VI) . 6 Remarkably, we could observe clear effects of the NO-GC inhibitor ODQ ( Figure 6 ), which suggest that constitutively active NO-GC is present in these cells. Because the NO-GC-associated cGMP pools and the proper localization of this enzyme are particularly important for heart function and pathophysiology, 40 it will be intriguing to generate targeted versions of red cGES-DE5 (eg, targeted to the plasma membrane) to dissect cGMP signaling inside the membrane signalosomes. The advantage of transgenic mice expressing a FRET biosensor is the possibility of combining them with experimental mouse models for hypertrophy and heart failure with subsequent analysis of cGMP in freshly isolated cells, as demonstrated by measurements in TAC myocytes ( Figure 4F) .
In contrast to less active NO-GC, cGMP levels could be strongly stimulated by CNP ( Figure 2C-2E) . Both ANP and CNP receptors GC-A and GC-B have been described in cardiac myocytes, but it is still controversial which one of these GCs plays a predominant role. 4, 43, 44 Here we found that GC-B activation by CNP leads to much more pronounced cytosolic cGMP signals, suggesting that this receptor might be particularly important for the regulation of cardiomyocyte cGMP. This is in line with the published and whole-heart functional data showing stronger CNP effects on contractility and phospholamban phosphorylation when compared with ANP ( Figure 3 ; Online Figure VI) . 33, 34 The constitutive NO-GC activity is balanced by the basal activity of PDEs involved in cGMP degradation (Figure 4 ). Unexpectedly, PDE3 was found to regulate cytosolic cGMP levels, whereas PDE2 and PDE5 showed only minor effects. The latter isoforms might be particularly important for local control of cGMP in subcellular compartments, as suggested in earlier studies. 6, 18, 45 PDE3 can degrade both cAMP and cGMP. It is often referred to as the cGMP-inhibited PDE, that is, cGMP can block cAMP degradation by PDE3, and thought to be mainly responsible for cAMP hydrolysis, because the V max values for cAMP hydrolysis are almost 10-fold higher than for cGMP as a substrate. 46, 47 Likewise, cAMP can inhibit the cGMP-PDE activity of PDE3. Indeed, the presence of cAMP as the competitive substrate in cardiomyocytes, stimulated with a low dose of the β-adrenergic agonist ISO to mimic physiological catecholamine levels present in the heart ( Figure 5A ), led to a reduction of the cilostamide effect on intracellular cGMP measured by ≈50%. However, even in this case, PDE3 contribution remained important. PDE activity profile measured by FRET does not exactly match the data from in vitro PDE activity assay performed with cardiomyocyte lysates (Online Figure V) . Because this assay is routinely done at very high substrate concentrations, such as 1 μmol/L cGMP, these in vitro conditions are vastly different from physiological low cGMP values in cardiomyocytes (by the factor of 100), possibly leading to a decrease of PDE3 activity and underestimation of its contribution. Our FRET approach works in intact cells at endogenous cGMP levels and provides a more sensitive and more physiological way to analyze PDE activity. At this point, it is worth mentioning again that we measured PDE inhibitor effects in the whole cytosolic compartment. Next, it will be interesting to do it in distinct subcellular microdomains, which is only possible with localized FRET sensors, but not with the classical biochemical assays. Therefore, we think that, compared with classical assays, our approach is more precise because it better reflects the behavior of intact cells.
PDE3 has been previously characterized as a PDE, which, together with PDE2, is crucial for the cGMP/cAMP crosstalk in neonatal rat cardiomyocytes. 9, 25 We studied this mechanism in the cytosol of adult mouse myocytes after β-adrenergic stimulation and found that cAMP elevation via cGMP-dependent PDE3 inhibition after CNP plays a predominant role in the cytosolic compartment of adult cardiomyocytes (Figure 7 ; Online Figure VI ). This mechanism might account for the initial increase in cardiac contractility observed in isolated hearts on CNP infusion, 34 as well as the positive inotropic effect of CNP in failing cardiomyocytes. 48 Moreover, this type of PDE3dependent cGMP/cAMP crosstalk, together with upregulation of PDE5 activity, has been shown to play an important role for the regulation of contractility in hypertrophied myocardium. 49 To further study cAMP/cGMP crosstalk, it is possible to generate double transgenic mice that express both sensors, the red cGES-DE5 sensor and Epac1-camps, to visualize cGMP and cAMP dynamics simultaneously. 28 In general, in vitro cGMP-PDE assays are not easy to perform at low substrate concentrations, and RIAs are usually done under complete PDE inhibition with IBMX. Therefore, our live cell FRET approach is a powerful way of analyzing the role of various PDEs in the regulation of physiologically low basal cGMP levels in intact adult cardiomyocytes. In addition, FRET measurements allow real-time monitoring and detailed kinetic analysis of responses to various pharmacological GC ligands and PDE inhibitors alone or in combination, in healthy and diseased adult cardiomyocytes. An important limitation of the method is the use of single isolated myocytes, which are not always directly comparable to the cells in intact myocardium. The cell isolation process might induce significant cellular stress and generation of oxidative species that can potentially affect the activities of GCs and PDEs. However, the rapid development of imaging techniques should soon allow FRET measurements to be performed in intact hearts for which the presented robust transgenic expression of the biosensor is indispensable. In conclusion, we think that our newly generated cGMP sensor mice will find a broad application to study cardiac cGMP signaling.
